DelveInsight’s “Bulimia Nervosa Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Bulimia Nervosa, historical and forecasted epidemiology as well as the Bulimia Nervosa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Bulimia Nervosa Market Report:
https://www.delveinsight.com/report-store/bulimia-nervosa-market
Some of the key facts of the Bulimia Nervosa Market Report:
The Bulimia Nervosa market size is anticipated to grow with a significant CAGR during the study period (2022-2036).
In April 2026, MDMA-Assisted Psychotherapy Study Progress: A clinical trial investigating the potential of MDMA-assisted psychotherapy for the treatment of bulimia nervosa was updated and moved toward the recruitment phase. The study aims to evaluate whether this therapeutic approach can enhance treatment effectiveness by alleviating anxiety and facilitating deeper psychological processing in individuals with bulimia nervosa.
In January 2026, Neurofeedback Study Advances Recruitment: Researchers at the Icahn School of Medicine at Mount Sinai continued enrolling participants in a clinical trial investigating functional near-infrared spectroscopy (fNIRS)-guided neurofeedback for women with bulimia nervosa. The study is evaluating whether this targeted neurofeedback approach can enhance inhibitory control and help alleviate core symptoms associated with the disorder.
Pharmacological therapy remains limited, with PROZAC (fluoxetine) being the only FDA-approved medication for bulimia nervosa at a dose of 60 mg/day. It provides moderate efficacy in reducing binge-purge frequency and relapse risk but is largely symptomatic rather than disease-modifying.
The lifetime prevalence rates for bulimia nervosa ranged from 0.3–4.6% in females and from 0.1–1.3% in males.
The pooled overall lifetime prevalence rate rose to 1.4% when using only studies that applied DSM-5 criteria (18%; all in Western countries).
According to a secondary analysis, during the period from 1990 to 2021, the number of individuals affected by bulimia nervosa increased by 67%, rising from 7,416,420 cases to 12,367,024 cases.
One-year prevalence of bulimia nervosa is 0.32% for females and 0.05% for males.
Key Bulimia Nervosa Companies: University of Cincinnati, Janssen-Cilag Farmaceutica, Sanofi, Mclean Hospital, and others
Key Bulimia Nervosa Therapies: Duloxetine, topiramate, rimonabant (SR141716), memantine, and others
The Bulimia Nervosa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bulimia Nervosa pipeline products will significantly revolutionize the Bulimia Nervosa market dynamics.
Bulimia Nervosa Overview
Bulimia Nervosa is a serious eating disorder characterized by recurrent episodes of binge eating, during which an individual consumes unusually large amounts of food in a short period while feeling a loss of control. These episodes are followed by compensatory behaviors aimed at preventing weight gain, such as self-induced vomiting, excessive exercise, fasting, or misuse of laxatives and diuretics.
To Know in detail about the Bulimia Nervosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bulimia Nervosa Market Forecast
Bulimia Nervosa Epidemiology
The Bulimia Nervosa epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bulimia Nervosa Epidemiology Segmentation:
The Bulimia Nervosa market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Bulimia Nervosa
Gender-specific Diagnosed Prevalent Cases of Bulimia Nervosa
Age-specific Diagnosed Prevalent Cases of Bulimia Nervosa
Total Treated Cases of Bulimia Nervosa
Download the report to understand which factors are driving Bulimia Nervosa epidemiology trends @ Bulimia Nervosa Epidemiology Forecast
Bulimia Nervosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bulimia Nervosa market or expected to get launched during the study period. The analysis covers Bulimia Nervosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bulimia Nervosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bulimia Nervosa Therapies and Key Companies
Duloxetine: University of Cincinnati
topiramate: Janssen-Cilag Farmaceutica
rimonabant (SR141716): Sanofi
memantine: Mclean Hospital
Discover more about therapies set to grab major Bulimia Nervosa market share @ Bulimia Nervosa Treatment Market
Bulimia Nervosa Market Drivers
Increasing prevalence of eating disorders, particularly among adolescents and young adults, is expanding the treatment-eligible population.
Growing awareness of mental health conditions and eating disorders is improving diagnosis rates and healthcare engagement.
Rising adoption of multidisciplinary treatment approaches, including psychotherapy, nutritional counseling, and pharmacotherapy, is supporting market growth.
Advancements in digital therapeutics, telepsychiatry, and remote behavioral health services are enhancing patient access to care.
Bulimia Nervosa Market Barriers
Stigma surrounding eating disorders and mental health conditions often leads to delayed diagnosis and underreporting.
Limited availability of approved pharmacological treatments restricts therapeutic options for patients.
High relapse rates and the chronic, recurrent nature of the disorder can complicate long-term disease management.
Variability in treatment response and patient adherence may affect clinical outcomes.
Shortages of specialized eating disorder treatment centers and trained healthcare professionals can limit access to care.
Scope of the Bulimia Nervosa Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Bulimia Nervosa Therapeutic Assessment: Bulimia Nervosa current marketed and Bulimia Nervosa emerging therapies
Bulimia Nervosa Market Dynamics: Bulimia Nervosa market drivers and Bulimia Nervosa market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Bulimia Nervosa Unmet Needs, KOL’s views, Analyst’s views, Bulimia Nervosa Market Access and Reimbursement
To know more about Bulimia Nervosa companies working in the treatment market, visit @ Bulimia Nervosa Clinical Trials and Therapeutic Assessment
Table of Contents
1. Bulimia Nervosa Market Report Introduction
2. Executive Summary for Bulimia Nervosa
3. SWOT analysis of Bulimia Nervosa
4. Bulimia Nervosa Patient Share (%) Overview at a Glance
5. Bulimia Nervosa Market Overview at a Glance
6. Bulimia Nervosa Disease Background and Overview
7. Bulimia Nervosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Bulimia Nervosa
9. Bulimia Nervosa Current Treatment and Medical Practices
10. Bulimia Nervosa Unmet Needs
11. Bulimia Nervosa Emerging Therapies
12. Bulimia Nervosa Market Outlook
13. Country-Wise Bulimia Nervosa Market Analysis (2022–2036)
14. Bulimia Nervosa Market Access and Reimbursement of Therapies
15. Bulimia Nervosa Market Drivers
16. Bulimia Nervosa Market Barriers
17. Bulimia Nervosa Appendix
18. Bulimia Nervosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
